Eli Lilly (NYSE:LLY | LLY Price Prediction) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough…
Four names are drawing analyst attention this week, with TD Cowen stepping back from Novo Nordisk A/S (NYSE:NVO | NVO Price Prediction), Truist trimming its target on Korn Ferry (NYSE:KFY), Morgan Stanley…
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday.…
Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early morning sell-off on Monday, the buy-the-dip buyers returned with a vengeance, and by the end…
Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the foundation for a larger and more intense sell-off. The combination of the…
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO | NVO Price Prediction) has dropped 22% in the past week and 56% over the past year, now sitting near its…
Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment was for the co-innovation lab. This article has been updated to reflect…
One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempic,…
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled its copycat semaglutide weight-loss pill over the weekend after threats of legal…
Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock…
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) has intensified following their latest fourth-quarter earnings reports. Novo Nordisk initially dominated…
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option…
Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline, 24/7 Wall St. projects healthy upside through the end of the decade.
Joel South Live Updates Here’s Why Nike is Soaring Today12:41pm ETNike dropped from about $69 to a low of $56.99 on weak China sales, declining gross margins, and a cautious outlook over the last…
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient —…
Rich Duprey 
